Arvinas CEO outlines strategy to rebuild pipeline after lead asset departure

In a recent episode of the Denatured podcast, Arvinas President and CEO Randy Teel discussed how the company is shifting focus to an early‑stage pipeline after its lead asset was out‑licensed or discontinued.

Teel explained that Arvinas is evaluating new opportunities in neurology and additional oncology indications, using a structured framework for target selection and portfolio balance.

He highlighted the strategic value of out‑licensing, noting that it can fund further research while allowing the company to apply its proven mechanism of action to new therapeutic areas.

The conversation underscored the discipline and leadership required for biotech firms to navigate inflection points when a flagship program ends.